The main aspects of using magne preparations in complex therapy of a comorbid patient with arterial hypertension

DOI: https://doi.org/10.29296/25877305-2021-10-17
Download full text PDF
Issue: 
10
Year: 
2021

Associate Professor V. Skvortsov, MD; A. Sabanov, MD; Associate Professor I. Rodionova,
Candidate of Medical Sciences; A. Gorbach Volgograd State Medical University, Ministry of Health of Russia

This article provides basic information on the effect of magnesium deficiency on the functional state of organs and systems, in particular in patients with cardiovascular pathology and comorbid conditions. The main causes of magnesium deficiency and the effects of drugs that compensate for its deficiency are considered. A clinical case of magnesium drug application as a supplement to the basic therapy of a patient with cardiovascular pathology and metabolic syndrome is considered.
Keywords: 
cardiology
magnesium
deficiency
comorbidity
cardiovascular diseases

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. 1. Safarjan A.S., Sargsjan V.D., Kamyshova T.V. i dr. Rol' magnija v razvitii serdechno-sosudistoj patologii i vozmozhnosti ee predotvraschenija i korrektsii preparatami magnija (chast' 1). Ratsional'naja farmakoterapija v kardiologii. 2019; 15 (5): 725–35 [Safaryan A.S., Sargsyan V.S., Kamyshova T.V. et al. The Role of Magnesium in the Development of Cardiovascular Diseases and the Possibility of their Prevention and Correction with Magnesium Preparations (Part 1). Rational Pharmacotherapy in Cardiology. 2019; 15 (5): 725–35. (in Russ.)]. DOI: 10.20996/1819-6446-2019-15-5-725-735
  2. 2. Safarjan A.S., Sargsjan V.D., Nebieridze D.V. Rol' magnija v razvitii serdechno-sosudistoj patologii i vozmozhnosti ee predotvraschenija i korrektsii preparatami magnija (chast' 2). Ratsional'naja farmakoterapija v kardiologii. 2020; 16 (3): 457–64 [Safaryan A.S., Sargsyan V.S., Nebieridze D.V. The Role of Magnesium in the Development of Cardiovascular Diseases and the Possibility of their Prevention and Correction with Magnesium Preparations (Part 2). Rational Pharmacotherapy in Cardiology. 2020; 16 (3): 457–64 (in Russ.)]. DOI: 10.20996/1819-6446-2020-02-16
  3. 3. Kerimov A.A., Alieva N.R. Voprosy diagnostiki i znachenija urovnja magnija v organizme cheloveka. Biomeditsina (Baku). 2016; 4: 8–12 [Kerimov A., Aliyeva N. Questions of diagnostics and value of magnesium levels in human organism. Biomeditsina (Baku). 2016; 4: 8–12 (in Russ.)]
  4. 4. Drapkina O.M., Gegenava B.B. Defitsit magnija v kardiologii. Ter arh. 2014; 86 (12): 104–6 [Drapkina O.M., Gegenava B.B. Magnesium deficiency in cardiology. Ter Arkh. 2014; 86 (12): 104–6 (in Russ.)]. DOI: 10.17116/terarkh20148612104-106
  5. 5. Mamedov M.N. Primenenie preparata magnija v kardiologicheskoj praktike. Rossijskij kardiologicheskij zhurnal. 2012; 17 (2): 72–4 [Mamedov M.N. Magnesium medication use in cardiology practice. Russian Journal of Cardiology. 2012; 17 (2): 72–4 (in Russ.)].
  6. 6. Akarachkova E.S., Vershinina S.V., Kotova O.V. Magnij v lechenii i profilaktike tserebrovaskuljarnyh zabolevanij. Kardiologija. 2012; 52 (9): 80–6 [Akarachkova E.S., Vershinina S.V., Kotova O.V. Magnesium in the treatment and prevention of cerebrovascular diseases. Kardiologiya. 2012; 52 (9): 80–6 (in Russ.)].
  7. 7. Gromova O.A. i dr. Nedostatochnost' magnija – dostovernyj faktor riska komorbidnyh sostojanij: rezul'taty krupnomasshtabnogo skrininga magnievogo statusa v regionah Rossii. Farmateka. 2013; 6: 116–29 [Gromova O.A. et al. Magnesium deficiency – a significant risk factor for comorbidity: results of large-scale screening of magnesium status in russian regions. Farmateka. 2013; 6: 116–29 (in Russ.)]
  8. 8. Oganov R.G., Simanenkov V.I., Bakulin I.G. i dr. Komorbidnaja patologija v klinicheskoj praktike. Algoritmy diagnostiki i lechenija. Kardiovaskuljarnaja terapija i profilaktika. 2019; 18 (1): 5–66 [Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019; 18 (1): 5–66 (in Russ.)]. DOI: 10.15829/1728-8800-2019-1-5-66
  9. 9. Baryshnikova G.A., Chorbinskaja S.A., Stepanova I.I. i dr. Defitsit kalija i magnija, ih rol' v razvitii serdechno-sosudistyh zabolevanij i vozmozhnost' korrektsii. Consilium Medicum. 2019; 21 (1): 67–73 [Baryshnikova G.A., Chorbinskaya S.A., Stepanova I.I. et al. Potassium and magnesium deficiency, its role in cardiovascular disease development and possibilities of correction. Consilium Medicum. 2019; 21 (1): 67–73 (in Russ.)]. DOI: 10.26442/20751753.2019.1.190240.
  10. 10. Nedogoda S.V., Barykina I.N., Salasjuk A.S. i dr. Ispol'zovanie kompleksnoj terapii v vedenii metabolicheskogo sindroma. Al'manah klinicheskoj meditsiny. 2015; 1 (1): 51–9 [Nedogoda S.V., Barykina I.N., Salasyuk A.S. et al. The use of multi-component therapy in the management of metabolic syndrome. Almanac of Clinical Medicine. 2015; 1 (1): 51–9 (in Russ.)]. DOI: 10.18786/2072-0505-2015-1-51-59
  11. 11. Nedogoda S.V., Vertkin A.L., Naumov A.V. i dr. Ozhirenie i komorbidnaja patologija v praktike poliklinicheskogo vracha. Chast' I: opredelenie, diagnostika. Ambulatornyj priem. 2016; 2 (1–4): 21–32 [Nedogoda S.V., Vertkin A.L., Naumov V.A. et al. Obesity and comorbid pathology in the outpatient practice of a physician. An Outpatient Appointment. 2016; 2 (1–4): 21–32 (in Russ.)].
  12. 12. Sizova Zh.M., Shih E.V., Bajchorov I.H. i dr. Polipragmazija i lekarstvennye vzaimodejstvija pri lechenii komorbidnyh bol'nyh arterial'noj gipertoniej v ambulatorno-poliklinicheskoj praktike. Poliklinika. 2015; 1 (2): 13–8 [Sizova Zh.M., Shikh E.V., Baychorov I.Kh., et al. Polypragmasia and drug interactions in the treatment of comorbid patients with arterial hypertension in outpatient practice. Polyclinic. 2015; 1 (2): 13–8 (in Russ.)].
  13. 13. Meghani S.H., Buck H.G., Dickson V.V. et al. The Conceptualization and Measurement of Comorbidity: A Review of the Interprofessional Discourse. Nurs Res Pract. 2013; 2013: 192782. DOI: 10.1155/2013/192782
  14. 14. Gorbacheva I., Sycheva Ju. Korrektsija disbalansa makroelementov pri gipertonicheskoj bolezni. Vrach. 2013; 12: 37–9 [Gorbacheva I., Sycheva Yu. Correction of macroelement imbalance in hypertensive disease. Vrach. 2013; 12: 37–9 (in Russ.)].
  15. 15. Trisvetova E.L. Defitsit magnija i serdechno-sosudistye zabolevanija: vremja dejstvovat'. Ratsional'naja farmakoterapija v kardiologii. 2014; 10 (1): 99–105 [Trisvetova E.I. Magnesium deficiency and cardiovascular diseases: time to act. Rational Pharmacotherapy in Cardiology. 2014; 10 (1): 99–105 (in Russ.)]. DOI: 10.20996/1819-6446-2014-10-1-99-105
  16. 16. Ostroumova O.D., Kochetkov A.I., Klepikova M.V. Lekarstvenno-indutsirovannyj defitsit elektrolitov. Chast' 2. Lekarstvenno-indutsirovannaja gipomagniemija. RMZh. 2020; 28 (12): 36–48 [Ostroumova O.D., Kochetkov A.I., Klepikova M.V. Drug-induced electrolyte disorder. Part 2. Drug-induced hypomagnesemia. RMJ. 2020; 28 (12): 36–48 (in Russ.)].
  17. 17. Lameris A.L., Monnens L.A., Bindels R.J. et al. Drug-induced alterations in Mg2+ homoeostasis. Clin Sci (London). 2012; 123 (1): 1–14. DOI: 10.1042/CS20120045
  18. 18. Gröber U. Magnesium and Drugs. Int J Mol Sci. 2019; 20 (9): 2094. DOI: 10.3390/ijms20092094
  19. 19. Govorin A.V., Filev A.P. Preparaty magnija pri zabolevanijah serdechno-sosudistoj sistemy. Ratsional'naja farmakoterapija v kardiologii. 2012; 8 (3): 463–8 [Govorin A.V., Filev A.P. Magnesium-containing drugs in cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2012; 8 (3): 463–8 (in Russ.)]. DOI: 10.20996/1819-6446-2012-8-3-463-468